Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
- First Posted Date
- 2005-11-29
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 120
- Registration Number
- NCT00259090
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 514
- Registration Number
- NCT00256698
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 750
- Registration Number
- NCT00253422
- Locations
- 🇬🇧
Royal Marsden - London, London, England, United Kingdom
🇬🇧Institute of Cancer Research - Sutton, Sutton, England, United Kingdom
Fulvestrant in Treating Patients With Advanced Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00244998
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 51
- Registration Number
- NCT00241449
- Locations
- 🇬🇧
Research Site, York, United Kingdom
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-04-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00217464
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2018-07-26
- Target Recruit Count
- 40
- Registration Number
- NCT00201864
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT00183963
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00146601
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Lowell General Hospital, Lowell, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Translational Oncology Research International
- Target Recruit Count
- 2
- Registration Number
- NCT00138125
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸Cancer Care Associates Medical Group, Inc, Redondo Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.